Article

Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies

2023-07-12

Abstract excerpt

<h4>ABSTRACT</h4> <h4>BACKGROUND</h4> Traditional value assessment frameworks are challenged in comprehensively assessing the societal value new therapies bring to individuals with rare, progressive, genetic, fatal, neuromuscular diseases such as Duchenne muscular dystrophy (DMD). <h4>OBJECTIVE</h4> To identify how value assessment frameworks may need to be adapted to measure the value to society of DMD therapies....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b61f3410-6217-549e-8eac-f91ca779502f
DOI: 10.1101/2023.07.11.23292507

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesDOI 10.1101/2023.07.11.23292507Read

Value-based genomic screening: exploring genomic screening for chronic diseases using triple value principles.Semantic proximity Read

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United StatesSemantic proximity Read

Is it ethical to reimburse “SMA Innovative Treatments” from government resources?Semantic proximity Read

Social and private value created through commercialization of Gilead Sciences’ innovative medicines for Hepatitis C and HIV: a cross-sectional analysisSemantic proximity Read

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read

Estimated Costs for Duchenne Muscular Dystrophy Care in BrazilSemantic proximity Read

Protocol for an eDelphi study to identify consensus on policy metrics which should be included in future assessments of the England Rare Diseases Action PlansSemantic proximity Read

Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experimentSemantic proximity Read

Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness resultsSemantic proximity Read

Using the OPUF approach to create a value set for the EQ-HWB-S: An exploratory feasibility studySemantic proximity Read

A Formal Additive Value Model for General Practitioner Compensation: Integrating Functional, Social, and Psychological DimensionsSemantic proximity Read

Estimated costs for Duchenne muscular dystrophy care in BrazilSemantic proximity Read